Active	Status	Sponsor type	Region	Phase	Filter
5 Active 4 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
London, Edythe D
NCT03787628: Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder	Completed	2	35	US	Cannabidiol (CBD) 600 mg, Placebo	University of California, Los Angeles, National Institute on Drug Abuse (NIDA)	Opioid-use Disorder	03/24	03/24
NCT06218056: Cannabidiol for Reducing Cigarette Use	Recruiting	2	120	US	Cannabidiol (CBD) 800 mg, Placebo	University of California, Los Angeles	Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence	12/26	12/26
NCT03059563: Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users	Terminated	1	62	US	Varenicline, Chantix, Placebo	University of California, Los Angeles, National Institute on Drug Abuse (NIDA)	Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse	09/23	09/23
NCT04553263: Relapse Prevention in Stimulant Use Disorder	Withdrawn	1	60	US	Contrave 8Mg-90Mg Extended-Release Tablet, Naltrexone HCl/Bupropion HCl 8 Mg-90 Mg, Bupropion, Wellbutrin, Zyban	University of California, Los Angeles	Stimulant Use, Relapse, Cognitive Function, ADHD	01/25	01/25
NCT05279053: Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers	Completed	N/A	58	US		University of California, Los Angeles	Cigarette Smoking, Tobacco Dependence, Sex	03/23	03/23